NCT00279058View on ClinicalTrials.gov

The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Metastatic Melanoma
Interventions
PROCEDURE

Immunotherapy treatment for melanoma

Trial Locations (1)

91 120

Hadassah Medical Organization, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER

NCT00279058 - The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 | Biotech Hunter | Biotech Hunter